Aggarwal Puneet, Mishra Pashupati Nath, Mathur V N, Velivela Kiran C, Khan Siraj, Deshmukh Prashant, Khalse Maneesha, Patel Kamlesh
Neurology, Max Super Specialty Hospital,, New Delhi, IND.
Neurosurgery, KH Advanced Brain and Spine Centre, Apollo KH Hospital, Vellore, IND.
Cureus. 2025 Feb 26;17(2):e79722. doi: 10.7759/cureus.79722. eCollection 2025 Feb.
Neuropathic pain of various etiology is the most commonly reported at primary clinics by patients. Patients experience moderate to severe chronic pain, impacting quality of life (QoL) and mood. The mainstay of the treatment includes gabapentinoid-based treatment to reduce pain severity and improve the QoL for the patients.
In a retrospective cross-sectional survey in India, the drug usability of gabapentinoid-based treatment in various neuropathic pain was studied. This included data collection from various neurological clinics across India that considered patient demographics, comorbidities, type of neuropathies, the percentage of patients receiving gabapentinoid-based treatment, the share of diabetic patients and diabetic neuropathy, and the severity of pain reported by patients.
The cross-sectional survey was conducted at 51 neurology clinics involving 2,251 patients. Patients presented with neuropathic pain of various etiologies, of which diabetic neuropathy was the most prevalent condition. Among the patients, 59.30% (1,252) consulted the neurologist for the first time, whereas 40.70% (860) of patients visited the clinic for follow-up. Neurologists prescribed gabapentinoid-based combination treatment as the main preferred treatment. Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) antidepressant, and nortriptyline, a tricyclic antidepressant (TCA), were the most preferred agents used in combination with pregabalin and gabapentin. Patients who visited for follow-up reported pain reduction and improved QoL with the treatment provided by the neurologists.
Gabapentinoid-based treatments combined with TCA and SSNRI are useful and well-accepted treatment modalities by neurologists in painful neuropathies. Gabapentinoids are non-opioids with no risk of abuse and addiction and were considered the first line of therapy for various types of neuropathic pain.
各种病因引起的神经性疼痛是患者在基层诊所最常报告的症状。患者经历中度至重度慢性疼痛，影响生活质量（QoL）和情绪。治疗的主要方法包括基于加巴喷丁类药物的治疗，以减轻疼痛严重程度并改善患者的生活质量。
在印度进行的一项回顾性横断面调查中，研究了基于加巴喷丁类药物的治疗在各种神经性疼痛中的药物可用性。这包括从印度各地的各种神经科诊所收集数据，这些数据涉及患者人口统计学、合并症、神经病变类型、接受基于加巴喷丁类药物治疗的患者百分比、糖尿病患者和糖尿病性神经病变的比例，以及患者报告的疼痛严重程度。
横断面调查在51家神经科诊所对2251名患者进行。患者表现出各种病因的神经性疼痛，其中糖尿病性神经病变是最常见情况。在这些患者中，59.30%（1252名）是首次咨询神经科医生，而40.70%（860名）患者是复诊。神经科医生将基于加巴喷丁类药物的联合治疗作为主要首选治疗方法。度洛西汀，一种选择性5-羟色胺和去甲肾上腺素再摄取抑制剂（SSNRI）类抗抑郁药，以及去甲替林，一种三环类抗抑郁药（TCA），是与普瑞巴林和加巴喷丁联合使用时最常用的药物。复诊患者报告称，神经科医生提供的治疗使疼痛减轻且生活质量得到改善。
基于加巴喷丁类药物的治疗与TCA和SSNRI联合使用，是神经科医生治疗疼痛性神经病变时有用且被广泛接受的治疗方式。加巴喷丁类药物是非阿片类药物，无滥用和成瘾风险，被视为各种类型神经性疼痛的一线治疗药物。
